Stock Research: Haemonetics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Haemonetics

NYSE:HAE US4050241003
32
  • Value
    22
  • Growth
    43
  • Safety
    Safety
    67
  • Combined
    29
  • Sentiment
    53
  • 360° View
    360° View
    32
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Haemonetics Corporation is a global healthcare company providing medical products and solutions. It operates in the healthcare industry, with segments in blood and plasma component collection, surgical suites, and hospital transfusion services. The company operates globally. In the last fiscal year, the company had a market cap of $3,585 million, profits of $764 million, revenue of $1,361 million, and 3,023 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 32 (better than 32% compared with alternatives), overall professional sentiment and financial characteristics for the stock Haemonetics are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Haemonetics. The consolidated Value Rank has an attractive rank of 67, which means that the share price of Haemonetics is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 67% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 53, which means that professional investors are more optimistic about the stock than for 53% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 43, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 22, meaning the company has a riskier financing structure than 78 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
Dividends USA
D.J. US Medical Equipment
S&P MIDCAP
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
67 93 68 99
Growth
43 13 63 9
Safety
Safety
22 31 33 4
Sentiment
53 68 81 97
360° View
360° View
32 52 90 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
74 67 51 58
Opinions Change
37 15 29 72
Pro Holdings
n/a 82 88 95
Market Pulse
72 74 75 80
Sentiment
53 68 81 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
67 93 68 99
Growth
43 13 63 9
Safety Safety
22 31 33 4
Combined
29 28 67 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
84 85 48 77
Price vs. Earnings (P/E)
58 53 48 79
Price vs. Book (P/B)
57 24 30 63
Dividend Yield
1 98 100 100
Value
67 93 68 99
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
43 8 20 10
Profit Growth
34 58 77 53
Capital Growth
54 12 53 36
Stock Returns
39 47 73 9
Growth
43 13 63 9
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
14 30 20 19
Refinancing
51 68 37 55
Liquidity
48 30 77 17
Safety Safety
22 31 33 4

Similar Stocks

Discover high‑ranked alternatives to Haemonetics and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.